Figure 1.

Mutations detected in tumor samples of colorectal cancer patients according to bevacizumab response status. Genes for which genetic mutations were detected in at least five study patients are depicted in an oncoprint plot and were ranked according to their observed mutation frequency in the overall study cohort. Patients were grouped according to their bevacizumab response status. Mutations were subdivided into variants with or without existing COSMIC ID. Variants without COSMIC ID were either truncating variants—including nonsense, frameshift, and splice-site variants or missense variants and in-frame indel variants. Additionally, the patient characteristics sex, age, MSI status, and total number of detected mutations are indicated for each patient.